Company Update (NYSE:OPK): Opko Health Inc. to Present Long-acting Human Growth Hormone Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology

OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016.

Twenty four month phase 2 efficacy, safety, pharmacokinetic, and pharmacodynamic data from OPKO’s long acting human growth hormone, hGH-CTP, in growth hormone deficient children will be presented.

OPKO will also hold a workshop for participating endocrinologists to review final phase 3 study plans.

OPKO expects to shortly initiate a global pivotal phase 3 study in pre-pubertal growth hormone deficient children to evaluate weekly single doses of hGH-CTP versus daily injections of a presently used growth hormone product. OPKO has a world-wide collaboration agreement with Pfizer Inc. for the development and commercialization of hGH-CTP.(Original Source)

Shares of Opko Health closed last Friday at $9.33, up $0.04 or 0.43%. OPK has a 1-year high of $10.54 and a 1-year low of $8.71. The stock’s 50-day moving average is $9.78 and its 200-day moving average is $10.02.

On the ratings front, OPK has been the subject of a number of recent research reports. In a report issued on August 16, Jefferies analyst Brandon Couillard reiterated a Hold rating on OPK. Separately, on August 9, J.P. Morgan’s Dana Flanders reiterated a Buy rating on the stock and has a price target of $14.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brandon Couillard and Dana Flanders have a total average return of 13.3% and -9.0% respectively. Couillard has a success rate of 73% and is ranked #152 out of 4147 analysts, while Flanders has a success rate of 17% and is ranked #3364.

Overall, 2 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $18.00 which is 92.9% above where the stock closed last Friday.

OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company. The company is engaged in discovering, developing, commercializing and expertise its novel and proprietary technologies with a focus to provide unmet medical needs through a range of develops solutions to diagnose, treat and prevent various conditions, including molecular diagnostics, point-of-care tests and proprietary pharmaceuticals and vaccines. It operates its business through two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment consists of pharmaceutical research and development operations in Chile, Mexico, Ireland, Israel and Spain. The Diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts